XML 24 R13.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity

3 Months Ended

Mar. 31, 2026

Stockholders’ Equity [Abstract]

Stockholders’ Equity

7. Stockholders’ equity

Warrants

As of March 31, 2026, the following table summarizes the status of our outstanding and exercisable warrants and related transactions since December 31, 2025 (in thousands, except weighted average exercise price and weighted average remaining contractual life data):

		Warrants outstanding and exercisable
		Warrants				Weighted Average Exercise Price				Aggregate Intrinsic Value				Weighted Average Remaining Contractual Life (in Years)
Balance, as of December 31, 2025			98			$	63.33			$	—				4.6
Balance, as of March 31, 2026			98			$	63.33			$	—				4.3

Share-based compensation payment plans

As of March 31, 2026, 105,212 shares of common stock were subject to outstanding awards under our share-based payment award plans and inducement grants. As of March 31, 2026, 429,529 shares of common stock were available for future grants of share-based payment awards under the TherapeuticsMD, Inc. 2019 Stock Incentive Plan.

The following table summarizes the status of our outstanding and exercisable options and related transactions since December 31, 2025 (in thousands, except weighted average exercise price and weighted average remaining contractual life data):

		Outstanding																Exercisable
		Options Awards				Weighted Average Exercise Price				Aggregate Intrinsic Value				Weighted Average Remaining Contractual Life (in Years)				Options Awards				Weighted Average Exercise Price				Aggregate Intrinsic Value				Weighted Average Remaining Contractual Life (in Years)
Balance, as of December 31, 2025			105			$	74.05			$	—				7.3				105			$	74.04			$	—				7.3
Balance, as of March 31, 2026			105			$	73.18			$	—				7.1				105			$	73.17			$	—				7.1

The following table summarizes the status of our RSUs and related transactions since December 31, 2025 (in thousands, except weighted average grant date fair value):

		RSUs awards outstanding
		RSUs				Weighted Average Grant Date Fair Value				Aggregate Intrinsic Value
Balance, as of December 31, 2025			26			$	1.15			$	41.57
Balance, as of March 31, 2026			26			$	1.15			$	—

As of March 31, 2026 and December 31, 2025, there were no outstanding PSUs remaining.

Share-based payment compensation cost

Share-based payment compensation expense for PSUs is based on 100% vesting which was a part of the termination benefits for all employees who were terminated in 2022. We recorded share-based payment award compensation costs related to previously issued options, RSU and PSUs totaling $2 and $23 thousand for the three months ended March 31, 2026 and 2025, respectively.

The unrecognized compensation costs as of March 31, 2026 of $25 thousand are expected to be recognized as share-based payment award compensation related to unvested RSUs over a weighted average period of 2.6 years. No tax benefit was realized due to a continued pattern of net losses.